Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Electronic Micropump Could Deliver Treatment to Specific Brain Region

By Drug Discovery Trends Editor | April 17, 2015

There is an exactness that must be taken into account when treating neurological disorders. In treating epilepsy, for example, a condition in which nerve cell activity in the brain is disturbed, causing seizures, a drug needs to be delivered directly to a specific brain region—but without negatively affecting healthy brain regions.

Scientists at the Institute of Systems Neuroscience (INS) in Marseille, France, with the help of scientists at the École des Mines de Saint-Étienne and Linköping University (Sweden), have developed a product: an electronic micropump which, when combined with an anticonvulsant drug, enables localized inhibition of epileptic seizure in brain tissue in vitro.

The micropump (20 times thinner than a hair strand) is made of a membrane, which has negative ions attached to its surface, and can attract small positively charged molecules. When an electrical current is applied, the flow of electrons generated projects these molecules—whether ions or medications—toward a target.

To test their technology, the researchers reproduced charged epileptic neurons in mice brains in vitro. When they injected GABA, a naturally-produced brain compound that inhibits neurons, into the hyperactive region using the micropump, they observed the following: GABA not just halted abnormal brain activity, it didn’t interfere with normal-functioning brain areas.

Although this research is in the early stages (the researchers are next working on in vivo animal models), it has implications for improved neurological treatments, down the line.

Epilepsy affects 65 million people around the world, according to the Epilepsy Foundation. 

Establish your company as a technology leader. For 50 years, the R&D 100 Awards, widely recognized as the “Oscars of Invention,” have showcased products of technological significance. Learn more. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE